SVRASavara Inc
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$123M
- 20% YoY
- Market cap
- $990M
- Employees
- —
- Net debt / EBITDA
- —
- −$42M net debt
- AI in 10-K
- 0.0
- mentions per 10K words
Takeover score 3 of 13
Fixable underperformance 1 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$5M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCYes56× of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo0% of assetsOver 40% of assets
- Shareholder dissentNo99% lowest supportAny vote under 80% support
Buyer economics 2 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AIYes0.0 per 10K words · 0th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$990M market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$2M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$41M | −$39M | −$60M | −$103M | −$124M | 20% |
| Net income | −$43M | −$38M | −$55M | −$96M | −$119M | 24% |
| Operating cash flow | −$40M | −$35M | −$51M | −$89M | −$101M | 13% |
| Capex | $57K | $9K | $296K | $25K | $22K | 12% |
| Stock-based comp | $3M | $2M | $4M | $10M | $14M | 46% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Nov 14, 2025 | Growth Equity Opportunities 17, LLC | SCHEDULE 13D/A | 12.0% | Passive |
| Mar 27, 2025 | Bain Capital Life Sciences Fund II, L.P. | SCHEDULE 13D/A | 10.0% | Passive |
| Aug 14, 2024 | Growth Equity Opportunities 17, LLC | SC 13D/A | 14.9% | Passive |
| Apr 12, 2024 | Bain Capital Life Sciences Fund II, L.P. | SC 13D/A | 10.0% | Passive |
| Jul 26, 2023 | Growth Equity Opportunities 17, LLC | SC 13D/A | 18.1% | Passive |
| Jul 19, 2023 | Bain Capital Life Sciences Fund II, L.P. | SC 13D/A | 10.0% | Passive |
| Mar 25, 2021 | Growth Equity Opportunities 17, LLC | SC 13D | 24.2% | Passive |
| Mar 17, 2021 | Bain Capital Life Sciences Fund II, L.P. | SC 13D/A | 10.0% | Passive |
| Dec 30, 2019 | Bain Capital Life Sciences Fund II, L.P. | SC 13D | 10.0% | Active |
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 2
- Net
- −$2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $10M | 196 | — |
| FY2024 | $5M | $4M | 65 | — |
| FY2023 | $4M | $6M | 303 | — |